New triple therapy could improve diabetes control
NCT ID NCT03899402
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding two extra medications (semaglutide and dapagliflozin) to insulin helps adults with type 1 diabetes control their blood sugar better than insulin alone or with just one extra drug. The 78 participants, aged 18-70 with a BMI of 25 or higher, will be followed for 12 months. The main goal is to see if the triple therapy lowers HbA1c, a key measure of long-term blood sugar control.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Diabetes and Endocrinology Research Center of WNY
Williamsville, New York, 14221, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an app and cash rewards tame type 1 diabetes in young adults?
- Smart insulin pump aims to end dangerous nighttime blood sugar swings
- Could diabetes be silently damaging your hearing?
- Hidden liver risk in type 1 diabetes: a new study investigates
- Can a wearable sensor outsmart diabetic ketoacidosis?
- Art as medicine: can drawing and painting help sick kids feel better about themselves?